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Simple Summary: Research is still required to establish the relationship between family history (FH)
and gastric cancer (GC) in relation to different histological types and anatomical sites. The present
work aimed to examine the influence of first-degree FH on the risk of GC, also according to the GC
location and histological type, including 5946 cases and 12,776 controls from 17 studies of 11 countries
in three continents participating in the Stomach Cancer Pooling (StoP) Project consortium. This
analysis confirms the effect of FH on the risk of GC, reporting an approximately doubled risk, and
provides further quantification of the risk of GC according to the subsite and histotype.
Abstract: Although there is a clear relationship between family history (FH) and the risk of gastric
cancer (GC), quantification is still needed in relation to different histological types and anatomical
sites, and in strata of covariates. The objective was to analyze the risk of GC according to first-degree
FH in a uniquely large epidemiological consortium of GC. This investigation includes 5946 cases and
12,776 controls from 17 studies of the Stomach Cancer Pooling (StoP) Project consortium. Summary
odds ratios (OR) and the corresponding 95% confidence intervals (CIs) were calculated by pooling
study-specific ORs using fixed-effect model meta-analysis techniques. Stratified analyses were
carried out by sex, age, tumor location and histological type, smoking habit, socioeconomic status,
alcohol intake and fruit consumption. The pooled OR for GC was 1.84 (95% CI: 1.64–2.04; I2 = 6.1%,
P heterogeneity = 0.383) in subjects with vs. those without first-degree relatives with GC. No
significant differences were observed among subgroups of sex, age, geographic area or study period.
Associations tended to be stronger for non-cardia (OR = 1.82; 95% CI: 1.59–2.05 for subjects with FH)
than for cardia GC (OR = 1.38; 95% CI: 0.98–1.77), and for the intestinal (OR = 1.92; 95% CI: 1.62–2.23)
than for the diffuse histotype (OR = 1.62; 95% CI: 1.28–1.96). This analysis confirms the effect of FH
on the risk of GC, reporting an approximately doubled risk, and provides further quantification of
the risk of GC according to the subsite and histotype. Considering these findings, accounting for the
presence of FH to carry out correct prevention and diagnosis measures is of the utmost importance.
Keywords: gastric cancer; family history; international consortium; meta-analyses
1. Introduction
Gastric cancer (GC) is the fifth leading cause of cancer by incidence and the third
leading cause of cancer death in both sexes worldwide. In 2018, there were an estimated
one million new GC cases and nearly 800 thousand deaths [1].
The most accepted model of human gastric carcinogenesis is a multistage model in
which both environmental and genetic factors are involved [2]. This includes family history
(FH), genetic susceptibility, shared environmental or lifestyle factors and/or a combination
of interactions. Between 80 and 90% of GCs are sporadic, 10 and 20% have a positive FH
and only between 1 and 3% show a clear Mendelian inheritance pattern [3]. Various studies
have investigated the role of FH in relation to GC, often reporting relative risks around
or over two for subjects with a positive FH of GC [4]. Such a strong association may be
explained, besides the genetic component, by environmental exposures—including smok-
ing habits, diet and particularly Helicobacter pylori infection—shared by family members.
Still, an unexplained large variability between risk estimates has been reported according
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to geographic area, ethnic group and sex, as well as the histological type and location of
GC [5]. Given the relatively small proportion of GC cases with a positive FH, only a few
large studies to date have been able to examine the role of FH on different locations and
histological types of GC, as well as in strata of covariates.
Five-year GC survival in most countries is less than 30% [6]. Therefore, it is important
to consider FH in prevention or early detection. The present work aims to examine the
influence of first-degree FH on the risk of GC, also according to the GC location and
histological type, in 17 studies from 11 countries in three continents participating in the
Stomach Cancer Pooling (StoP) Project consortium.
2. Materials and Methods
The StoP Project is a consortium of epidemiological studies on gastric cancer. A
detailed description of its aims and methods has been provided elsewhere [7]. Inclusion
criteria for study participation were: case–control study design, including nested case–
control within cohort studies, and inclusion of at least 80 cases of incident, histologically
confirmed GC (including both cardia and non-cardia locations). In addition, the original
questionnaires and useful information were collected to help with data handling from
studies, in order to optimize data harmonization.
For this analysis, the studies were selected from the StoP consortium studies that
had both the family history information and the covariates that we used in the models.
This work is based on the second data release of the StoP Project, where 17 studies [8–25]
conducted in 11 countries had data on the FH of GC and were examined, including a total of
5946 cases and 12,776 controls. The following data were extracted: (i) main study variables,
including study design, geographic area, study period, single center/multicentric study
and study center if multicentric; (ii) relevant covariates, including sex, age, education/social
class, body mass index, total alcohol consumption, smoking habit, H. pylori infection and
consumption of fruit and vegetables; (iii) specific cancer-related variables (for cases only),
including cancer subsite and histotype; (iv) FH of GC among first-degree relatives (parents,
siblings and offspring). All of the above variables were harmonized centrally according to
a pre-specified format. Furthermore, any additional information related to the FH of GC
available in each study (e.g., age at GC occurrence in relatives, type of relative affected)
was considered.
The StoP Project received ethical approval from the University of Milan Review Board
(reference 19/15 on 1 April 2015).
To estimate the association between FH and GC, a two-stage modeling approach was
used [26]. First, the association in each study was assessed by calculating the odds ratio (OR)
and the corresponding 95% confidence interval (CI) using multivariate logistic regression
models including terms for sex, age, socioeconomic level, smoking status and alcohol
consumption. In the second stage, summary effect estimates were computed by pooling
study-specific ORs using fixed-effect model meta-analysis techniques. Heterogeneity
between studies was evaluated using the Q test statistics and quantified using I2—that is,
the proportion of total variation contributed by between-study variance [27].
To investigate whether the role of FH was heterogeneous across strata of selected
covariates, analyses stratified by sex, age, socioeconomic status, GC location (cardias/non
cardias), histological subtype (intestinal, diffuse), tobacco smoking, socioeconomic status,
alcohol intake, fruit consumption and H. pylori infection were carried out. Additional
analyses were carried out according to type of study, control selection system (matched
or by frequency), source of controls (population or hospital) and study period (XX or XXI
century).
3. Results
The main characteristics of the StoP Project studies included in the present analysis
are shown in Table 1. Most studies were conducted in European countries (82.3% of the
controls, and 77.9% of the cases). Overall, 15.8% of cases (n = 942) and 7.7% of the controls
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(n = 979) had an FH of stomach cancer in first-degree relatives, ranging from 4.4 to 23.0%
among cases, and from 1.0 to 16.8% among controls.
Table 1. Main characteristics of the StoP Project studies included in the analyses.
StoP
Study ID






1 Milan, Italy 1985–1997 CC, hospital-based 97 768 110 2081 La Vecchia et al. [8]
3 Milan, Italy 1997–2007 CC, hospital-based 30 230 31 547 Foschi et al. [9]
4 Rome, Italy 2006–2010 CC, hospital-based 12 152 16 411 De Feo et al. [10]
5 Four areas, Italy 1985–1987 CC, population-based 213 1016 138 1159 Palli et al. [11]
6 Athens, Greece 1981–1984 CC, hospital-based 8 86 1 97 Lagiou et al. [12]
8 Taixing, Jiangsu, China 2000 CC, population-based 31 206 14 415 Mu et al. [13]
9 Moscow, Russia 1996–1997 CC, hospital-based 74 433 76 593 Zaridze et al. [14]
10 Ardabil, Iran 2004–2005 CC, population-based 31 217 24 394 Pourfarzi et al. [15]
11 Ardabil, Iran 2005–2007 CC, population-based 27 286 19 304 Pakseresht et al. [16]
13 Yangzhong, China 1995 CC, population-based 9 133 16 433 Setiawan et al. [17]
17 North of Portugal 2001–2006 CC, population-based 134 584 68 612 Lunet et al. [25]
21 Ten provinces, Spain 2008–2013 CC, population-based 70 435 208 3418 Castaño-Vinyals et al. [18]
22 Five counties, Sweden 1989–1995 CC, population-based 111 561 155 1164 Ye et al. [19]
23 Two provinces, Spain 1995–1999 CC, hospital-based 30 367 23 433 Santibañez et al. [20]
28 Brazil-Brazilian origin 1991–1994 CC, hospital-based 10 226 4 226 Nishimoto et al. [22]
29 Brazil-Japanese origin 1991–1994 CC, hospital-based 17 93 25 186 Hamada et al. [23]
30 Japan 1998–2002 CC, hospital-based 38 153 51 303 Machida-Montani et al. [24]
Table 2 shows the frequency distribution of cases and controls according to the selected
covariates. Cases were more frequently male (63.7% vs. 58.3%), aged 65 or older (50.5%
vs. 43.0%) and of a low socioeconomic status (63.9% vs. 52.1%) compared to controls.
Furthermore, cases were more frequently current smokers (28.9% vs. 25.8%) and reported
a high alcohol intake (14.5% vs. 10.6%) and a low consumption of fruit (36.3% vs. 29.0%)
compared to controls.
In all studies, first-degree FH was positively related to GC, with ORs ranging between
1.46 and 11.26 (Figure 1). The differences observed were statistically significant in 10 out
of the 17 studies included. The pooled OR of all studies was 1.84 (95% CI = 1.64–2.04;
I2 = 6.1%, Pheterogeneity = 0.383).
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Table 2. Distribution of cases and controls according to selected covariates.
Variables
Cases Controls
n % n %
Sex
Male 3790 63.7 7454 58.3
Female 2156 36.3 5322 41.7
Age
18–49 759 12.8 2553 20.0
50–65 2184 36.7 4724 37.0
65–74 2171 36.5 3940 30.8
75–106 832 14.0 1557 12.2
Missing 0 0.0 2 0.0
Socioeconomic status
Low 3799 63.9 6488 50.8
Medium 1543 26.0 3760 29.4
High 501 8.4 2198 17.2
Missing 103 1.7 330 2.6
Smoking habit (1)
Current 1720 28.9 3255 25.5
No 4132 69.5 9386 73.4
Missing 94 1.6 135 1.1
Alcohol intake g of ethanol/day
Never 1526 25.7 3375 26.4
Low (≤12) 1190 20.0 3468 27.1
Intermediate
(>12–47) 1745 29.4 3047 23.9
High (>47) 860 14.5 1353 10.6
Missing 625 10.5 1533 12.0
Fruit intake (2)
Low 2157 36.3 3701 29.0
Medium 1872 31.5 4109 32.2
High 1685 28.3 4293 33.6
Missing 232 3.9 673 5.3
H. pylori infection
Positive 688 11.6 3662 28.7
Negative 1661 27.9 1252 9.8
Missing 3597 60.5 7862 61.5
(1) No: never and former; (2) defined according to study-specific tertiles.
Regarding the analysis of the type of family member affected, Figure 2 shows that
the pooled OR for siblings was higher than for parents (1.62; 95% CI = 1.20–2.05, and 1.54;
95% CI = 1.28–1.80, respectively). No significant heterogeneity was observed.
Figure 3 shows the results from the stratified analyses. No significant differences were
found by sex, +68% in men and +91% in women. Thirteen and fourteen studies provided
information on the location of cardia and non-cardia GC, respectively. Of the 695 cardia GC
cases, 92 (13.2%) had a first-degree FH of GC, while 648 (17.6%) of the 3676 non-cardia GC
cases had a first-degree FH of GC. The pooled ORs were 1.38 (95% CI = 0.98–1.77) and 1.82
(95% CI = 1.59–2.05), respectively. Twelve studies reported information on the histological
classification of GC. Of the 2030 intestinal GC cases, 365 (18.0%) had a first-degree FH of
GC, yielding a pooled OR of 1.92 (95% CI = 1.62–2.23). The diffuse histological GC type
was reported in 1170 cases, with 169 (14.4%) having a first-degree FH of GC. The pooled
OR for all studies was 1.62 (95% CI = 1.28–1.96). There were no significant differences
according to age, smoking habit, socioeconomic status, alcohol intake, fruit consumption
or H. pylori infection.
Furthermore, no significant differences were observed according to whether the stud-
ies were performed in European (OR = 1.84, 95% CI = 1.62–2.06) or non-European popu-
lations (OR = 1.86, 95% CI = 1.33–2.38); were matched (OR = 1.83, 95% CI = 1.30–2.36)
or not-matched (OR = 1.85, 95% CI = 1.63–2.07); and were multicentric (OR = 1.83;
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95% CI = 1.57–2.09) or not (OR = 1.87, 95% CI = 1.54–2.21). Modest differences were ob-
served according to the type of controls (hospital-based controls: OR = 1.76,
95% CI = 1.43–2.09; population-based controls: OR = 1.90, 95% CI = 1.64–2.15), and to
the study period before the year 2000 (OR = 1.75, 95% CI = 1.51–1.98) or after the year 2000
(OR = 2.11, 95% CI = 1.72–2.50).
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4. Discussion
The results of this uniquely large collaborative study confirm and quantify the influ-
ence of FH on the development of GC better than previously available studies. History of
GC in a first-degree relative has been found to increase the risk of GC by about 85%. In this
pooled investigation, results were suggestive of a possible higher risk of non-cardia than
of cardia GC in subjects with a positive FH of gastric cancer, whereas no relevant differ-
ences were observed in strata of sex, in the histological type of GC or in the characteristics
analyzed in epidemiological studies.
The family aggregation of GC is due to a complex interaction between genetic inheri-
tance and environmental and lifestyle factors [28]. It is known that between 10 and 20% of
people who develop GC have a FH, but only part of this can be attributed to hereditary
syndromes. The three primary familial gastric cancers include hereditary diffuse gastric
cancer [3], familial intestinal gastric cancer and gastric adenocarcinoma and proximal
polyposis of the stomach, caused by germline mutations in genes such as CDH1, CTNNA1
and APC [29]. The remaining part may be due to low-penetrance genes, which, due to
their interaction with the family-shared environment, have an important influence [30].
In this way, the genetic inheritance, the unique environment of each individual and the
aforementioned family-shared environment can be divided into three pathways of GC
development. A study conducted among twins found that these causes account for 28%,
62% and 10% of the variation in GC susceptibility, respectively [31].
Our results do not show relevant differences according to sex. Though findings of
different studies have varied, with some of them reporting a stronger risk related to FH
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among women [32], our finding is broadly consistent with the conclusions of several re-
views [8,11,16,20]. Additionally, our results on the GC subsite are consistent with those
from a meta-analysis, indicating that FH has a greater relative risk (RR) on non-cardia GC
(RR = 1.97; 95% CI = 1.72–2.25) than on cardia GC (RR = 1.46; 95% CI = 0.89–2.39) [28].
Kharazmi et al. also showed similar results in a nationwide Swedish cohort study,
where the standardized incidence ratio (SIR) of cardia GC associated with a positive
FH of cancer at the same subsite was lower (SIR = 1.70; 95% CI = 1.10–2.50) compared
to non-cardia subclasses—antrum (SIR = 5.5; 95% CI = 2.4–11.00) and body (SIR = 4.6;
95% CI = 2.6–7.4) [33]. A large percentage of non-cardia GC cases are attributed to H. pylori
infection and, therefore, are more likely associated with family transmission [33]. On the
other hand, cardia GC is more likely related to lifestyle factors, with issues such as obesity
(increases the risk of cardia GC by 82%) [34–36], gastroesophageal reflux (increases the risk
two to four times) [19,37] and tobacco smoking [38].
The results of the present study show a higher risk of GC when the affected rel-
atives were siblings rather than parents, which is in line with previous studies report-
ing that the association tends to be stronger among siblings than between parents and
offspring [5,28,39,40]. However, one of the limitations of our study is that neither offspring
nor the age at diagnosis of the affected family member could be included due to the small
sample available for these specific analyses.
Regarding the histological type of GC, our results show that a FH of GC is associated
with both intestinal and diffuse subtypes, which is consistent with findings from the
prospective Alpha-Tocopherol, Beta-Carotene (ATBC) Cancer Prevention Study [28], which
suggested similarly increased risks in both histological subtypes of GC (intestinal: HR 1.53,
95% CI 0.92–2.55; diffuse: HR 1.47, 95% CI 0.72–3.03). However, by taking advantage of the
study consortium approach, our findings were based on a larger number of cases for both
histotypes, and therefore our estimates are more robust.
H. pylori infection is the major environmental factor in gastric carcinogenesis. As
in our study, another investigation [41] showed that patients with an FH and H. pylori
infection had a slightly higher risk of GC than those without H. pylori infection. However,
these differences were not significant.
No significant differences were found when the geographical origin of the samples
of the studies included (European vs. non-European populations) was analyzed. Most
previous studies on FH and GC were conducted in Asian countries, in North America
and in Northern Europe [9], and this analysis has the advantage of including studies
from less frequently considered areas (i.e., eight studies were from the Mediterranean
region, two from Iran and two from Brazil). Furthermore, the pooled analysis patient-level
approach allows for a direct comparison between estimates of different geographic areas,
by limiting methodological variation (through centralized data harmonization, using the
same adjustment terms in the models, etc.).
Only moderate differences were observed in relation to studies based on hospital-
and population-based controls. A higher risk of GC related to FH emerged for studies
conducted after the year 2000, as compared to those conducted earlier. This may be due
to a decrease in the weight of environmental factors, particularly H. pylori infection and
tobacco smoking, with respect to FH [42,43].
As strengths of the study, there are 5946 cases and 12,776 controls available for the
analysis, accompanied by a wide variety of predictor variables, providing an adequate
statistical power. Furthermore, this project is a collaborative framework, contributing
with varied geographical origins. In addition, we assessed the relationship between FH
and GC by location and histological types. The most important difference between our
work and the rest of the studies and meta-analyses is that, in our case, we worked with a
consortium of studies, meaning we directly used the study data instead of the ORs of the
published articles. This allows us to adjust all studies for the same variables and to have
more homogeneity in the results.
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5. Conclusions
Our results confirm and further quantify the effect of FH on the development of GC.
Subjects with an FH of GC among first-degree relatives have an approximately doubled
risk of GC occurrence. It is important to take into account the presence of an FH to carry
out GC prevention measures, both primary and secondary, i.e., early diagnosis.
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